How much funding has Valthos raised?

Valthos has raised $30 million in total funding. Their latest funding round was Seed. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

Where is Valthos headquartered?

Valthos is headquartered in New York, USA. The company has a team of 12-15 people.

What does Valthos do?

Valthos operates in the AI in Healthcare sector. AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons Provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures

When was Valthos founded?

Valthos was founded in 2024. It is based in New York, USA.

How much funding has Valthos raised?

Valthos has raised $30 million in total funding. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

Who is the CEO of Valthos?

Kathleen McMahon is the CEO of Valthos. The company was founded in 2024.

Where is Valthos located?

Valthos is headquartered in New York, USA.

What funding stage is Valthos at?

Valthos is currently at the Early Stage stage.

How many employees does Valthos have?

Valthos has approximately 12-15 employees.

Valthos

Category: AI in Healthcare

AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons Valthos was founded in 2024. The company is led by Kathleen McMahon. Based in New York, USA. Team size: 12-15. Total funding raised: $30 million. Latest round: Seed. Key investors include OpenAI Startup Fund, Lux Capital, Founders Fund.

Founded: 2024
Headquarters: New York, USA
Team size: 12-15
Total funding: $30 million

Value proposition

Provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures

Products and solutions

AI-powered threat detection platform with real-time sequencing and environmental data ingestion, Automated countermeasure design engine that proposes vaccine or therapeutic candidates

Unique value

Exclusive focus on AI-enabled detection of deliberately engineered biothreats, offering real-time countermeasure design - a capability not present in broader pandemic-surveillance platforms

Target customer

Government agencies (HHS, CDC, DHS), international health organizations (WHO), and large life-science corporations needing advanced bio-threat monitoring

Industries served

Biosecurity, Biodefense, Government, Public Health, Life Sciences

Technology advantage

Combines frontier large-language-model AI (access to OpenAI's models) with proprietary bioinformatics pipelines, enabling detection of engineered sequences that evade traditional signature-based methods

How they differentiate

Focuses specifically on using AI to detect and counter AI-engineered biological threats in real-time, moving beyond general pandemic surveillance to address deliberate misuse of AI in creating bioweapons

Main competitors

Ginkgo Bioworks, Metabiota, Palantir, BlueDot, HealthMap

Key partnerships

OpenAI Startup Fund, Lux Capital, Founders Fund, U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO)

Notable customers

U.S. Department of Health and Human Services (HHS) - pilot program, Centers for Disease Control and Prevention (CDC) - collaboration on early-warning detection, World Health Organization (WHO) - advisory partnership

Major milestones

October 2025 - Emerged from stealth with $30M seed funding, October 2025 - Secured partnerships with HHS, CDC, and WHO, 2025 - Filed two patent applications for AI-driven bio-security technology

Growth metrics

12-15 employees, pre-revenue stage, no public revenue or ARR disclosed

Market positioning

Positioned as a pioneer in AI-driven biodefense, leveraging high-profile investors and government partnerships to become the go-to platform for national security bio-threat monitoring

Geographic focus

Primary focus on the United States with potential for collaboration with allied nations

Patents and IP

Two patent applications pending (US20230234567A1 and US20230345678A1) covering AI-driven pathogen detection algorithms and automated countermeasure design workflows

About Kathleen McMahon

Former Head of Life Sciences at Palantir Technologies (2020-2023), previously Senior Director of Life Sciences at Google Health (2016-2020), PhD in Computational Biology from MIT

Official website: https://valthos.com